图文详情
I-BET432, a BET inhibitor, targets both the N-terminal (BD1) and C-terminal (BD2) bromodomains of BRD4, exhibiting pIC50 values of 7.5 and 7.2, respectively. As an orally administered candidate, I-BET432 holds potential for research in various oncology and inflammatory diseases.